20776-63-0

Basic information

• Product Name: 2-AMINO-4,6-DICHLOROBENZOIC ACID
• Synonyms: 2-AMINO-4,6-DICHLOROBENZOIC ACID;BUTTPARK 49\07-45;2-AMINO-4,6-DICHLOROBENZOIC ACID FOR SYN;2-Amino-4,6-dichlorobenzoic acid for synthesis
• CAS NO: 20776-63-0
• Molecular Formula: C₇H₅Cl₂NO₂
• Molecular Weight: 206.03
• Mol File: 20776-63-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 178.0-178.5 °C (decomp)
• Boiling Point: 375.2°Cat760mmHg
• Flash Point: 180.7°C
• Appearance: /
• Density: 1.607g/cm³
• Vapor Pressure: 2.7E-06mmHg at 25°C
• Refractive Index: 1.658
• Storage Temp.: Store below +30°C.
• Solubility: 1.25g/l
• PKA: 3.42±0.25(Predicted)
• CAS DataBase Reference: 2-AMINO-4,6-DICHLOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4,6-DICHLOROBENZOIC ACID(20776-63-0)
• EPA Substance Registry System: 2-AMINO-4,6-DICHLOROBENZOIC ACID(20776-63-0)

Safety Data

• Statements: 36
• Safety Statements: 26
• WGK Germany: WGK 3 highly water endangering
• Hazardous Substances Data: 20776-63-0(Hazardous Substances Data)

Usage

General Description

2-Amino-4,6-Dichlorobenzoic Acid is a chemical compound that contains chlorine, benzene, and an amino group. It typically appears as an off-white or colorless crystalline solid and falls under the category of organochlorides. 2-AMINO-4,6-DICHLOROBENZOIC ACID can exhibit various pharmacological activities depending upon its molecular composition. It is essentially used as an intermediate in the synthesis of more complex chemical compounds. Its use and handling should be with great caution due to its hazardous properties.

InChI:InChI=1/C7H5Cl2NO2/c8-3-1-4(9)6(7(11)12)5(10)2-3/h1-2H,10H2,(H,11,12)

Upstream product

• 18711-15-4 4,6-dichloro-1H-indole-2,3-dione 

Downstream Products

• 1083418-98-7 2,4-dichloro-6-[(4-methyl-2-morpholin-4-yl-thiazole-5-carbonyl)-amino]-benzoic acid 
• 1000860-21-8 5,7-dichloro-3-(4-chlorobenzyl)quinazoline-2,4(1H,3H)-dione 
• 1000859-37-9 2-amino-4,6-dichloro-N-(4-chlorobenzyl)benzamide 
• 1044871-15-9 5,7-dichloro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-3H-quinazolin-4-one 
• 1044872-58-3 2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-5,7-dichloro-3H-quinazolin-4-one 
• 1246250-35-0 5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one 
• 1246250-36-1 2-[4-(2-bromo-ethoxy)-3,5-dimethylphenyl]-5,7-dichloro-3H-quinazolin-4-one 
• 1436690-93-5 2-(3,5-dimethylphenyl)-5,7-diisobutylquinoline 
• 1436690-90-2 5,7-dichloro-2-(3,5-dimethylphenyl)quinoline 
• 1346679-12-6 tert-butoxycarbonylmethyl 4,6-dichloro-2-iodobenzoate 
• 1346679-06-8 methyl 4,6-dichloro-2-iodobenzoate 
• 1346679-10-4 4,6-dichloro-2-iodobenzoic acid 

Relevant articles and documents

NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Disclosed herein are novel substituted-1H-quinazoline-2,4-dione derivatives, a preparation method thereof, and a pharmaceutical composition containing the same. The novel substituted-1H-quinazoline-2,4-dione derivatives are excellent in binding affinity a

Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists

A 5,7-dichloro-3-phenyl-3-methyl-quinoline-2,4-dione (11a) has been identified in a random screen as a lead for 5-HT6 antagonist. During the lead optimization process, several analogs were synthesized and their biological activities were investigated. Within this series, several compounds display high binding affinity and selectivity for the 5-HT6 receptor. In particular, 3-(4-hydroxyphenyl)-3-methyl-quinoline-2,4-dione (12f) exhibits high affinity (Ki = 12.3 nM) for 5-HT6 receptor with good selectivity over other serotonin and dopamine (D1-D4) receptor subtypes. In a functional adenylyl cyclase stimulation assay, this compound exhibited considerable antagonistic activity (IC50 = 0.61 μM).

3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same

The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones , or a pharmaceutically acceptable salt thereof acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.